A. González‐Martín

发表

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Ignace Vergote, Christian Marth, Sven Mahner, 2016, The New England journal of medicine.

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

M. Climent, M. Regan, P. Francis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on randomized trials on recurrent disease.

A. González‐Martín, A. González-Martín, Antonio González-Martín, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy

A. González‐Martín, 2005, International Journal of Gynecologic Cancer.

Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy

A. González‐Martín, A. González-Martín, 2005, International Journal of Gynecologic Cancer.

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

C. Balañà, J. Rifá, A. Cervantes, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

SEOM guideline in ovarian cancer 2014

I. Bover, A. Redondo, A. González‐Martín, 2014, Clinical and Translational Oncology.

Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.

P. Ruff, N. Colombo, G. Scambia, 2020, Gynecologic oncology.

The BRCA Gene in Epithelial Ovarian Cancer

A. Patiño-García, A. González‐Martín, J. Villamayor, 2022, Cancers.

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.

I. Ray-Coquard, A. Leary, L. Poulain, 2020, The Lancet. Haematology.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

J. Baselga, N. Robert, D. Miles, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

N. Yanaihara, A. Okamoto, J. Ledermann, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Corrections to "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

F. Landoni, N. Colombo, C. Marth, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel chemotherapy approaches in chemoradiation protocols.

R. Colomer, A. González‐Martín, J. Hornedo, 2008, Gynecologic oncology.

Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update.

A. Poveda, A. González‐Martín, A. González-Martín, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.

J. Ledermann, S. Lheureux, A. Barnicle, 2022, Gynecologic oncology.

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

J. Serra-Musach, M. Pujana, P. Nuciforo, 2016, Oncotarget.

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Richard G. Moore, B. Monk, Aalok Kumar, 2022, Gynecologic oncology.